[Experimental study on antitumor effect of cisplatin-microcapsule].
CDDP-microcapsule (CDDP-mc) was prepared in the search for method for administering anti-cancer agents and has been examined for its properties, vital reaction and antitumor effect. In the present study, the results of the examination and possibility of application of CDDP-mc are reported. 1) It took 48 hours for CDDP to be released from the microcapsule into saline. 2) CDDP-mc size is 80-200 microns, and it contains 0.645mg of CDDP per mg of microcapsule. It was available as a drug enabling us to introduce a high concentration of CDDP into tumor tissue. 3) The side effects of CDDP-mc on animals (rabbit and rat) were more limited than those of ordinary CDDP solution and slight, especially for intraperitoneal or local injection. Intraarterial infusion of CDDP-mc, however, causes transitory palsy of the treated lower extremity probably due to embolism. 4) Its intraperitoneal administration was much more effective than the ordinary CDDP solution against Yoshida's sarcoma implanted in rats. 5) The subcutaneous administration of CDDP-mc was more effective compared to ordinary solution of CDDP. 6) The above results suggested that CDDP-mc is clinically applicable to the treatment of ovarian cancer and uterine cancer when administered intraperitoneally and locally (intra-tumor).
Ohta
S
S
Department of Obstetrics and Gynecology, Hirosaki University Medical School.
Sato
S
S
Saito
Y
Y
Fukushi
A
A
D000818:Animals; D002214:Capsules; D002945:Cisplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008297:Male; D009368:Neoplasm Transplantation; D010316:Particle Size; D011817:Rabbits; D051381:Rats; D012517:Sarcoma, Yoshida / Q000188:drug therapy* / Q000378:metabolism; D012995:Solubility; D014018:Tissue Distribution; D014599:Uterus / Q000378:metabolism
D002214:Capsules; D002945:Cisplatin